Catalyst Wire Dossier Catalyst Wire Dossier

Valneva SARS-CoV-2 vaccine candidate (inactivated, adjuvanted)

inactivated SARS-CoV-2 vaccine with adjuvant · Valneva Austria GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Valneva SARS-CoV-2 vaccine candidate (inactivated, adjuvanted), covering 2022-03-24 to 2022-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects [Phase 1, Phase 2]

See pricing